Biopharmaceutical company Arcus Biosciences has expanded its existing strategic relationship with Chinese company WuXi Biologics to discover anti-CD39 antibodies using the latter’s proprietary technology.
Gilead Sciences has partnered with Arcus Biosciences to jointly develop and commercialise current and future cancer therapeutic candidates in the latter’s pipeline.